The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects lesions and signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Select Collaborators, Customers, & Partners
Eyenuk, Inc. Combines Artificial Intelligence Disease Detection with Human Grading to Launch the EyeScreen™ Human + AI Diagnostic Service
APRIL 11 2019, LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today the launch of the EyeScreen™ Human...
Combining the high accuracy of AI disease detection with the accepted practice of human grading, the EyeScreen™ Service for diabetic retinopathy (DR) identifies cases of referable DR in any clinical setting with extremely high accuracy....
Eyenuk To Provide Artificial Intelligence (AI) Eye Screening to Thousands of Italians Through Collaboration With Ambrosian Ophthalmic Center in February
– 30 Centers Across Italy Will Provide AI Eye Screening for Diabetic Retinopathy, the Leading Cause of Vision Loss Among Working-age Adults – LOS ANGELES–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services...